Characterization of glucagon-like peptide-1 receptor-binding determinants

Journal of Molecular Endocrinology

Volumn 25, Issue 3, 2000, Pages 321-335

  Xiao, Q ^a   Jeng, W ^a   Wheeler, M B ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HORMONE RECEPTOR;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CROSS LINKING; HORMONE RECEPTOR INTERACTION; HORMONE STRUCTURE; HORMONE SYNTHESIS; IC 50; INSULIN LIKE ACTIVITY; MUTAGENESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; WESTERN BLOTTING;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; CELL LINE; CHIMERA; CLONING, MOLECULAR; COS CELLS; GENE EXPRESSION; HUMANS; INSECTS; LIGANDS; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE FRAGMENTS; RATS; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, GLUCAGON;

EID: 0034522536     PISSN: 09525041     EISSN: None     Source Type: Journal    
DOI: 10.1677/jme.0.0250321     Document Type: Article

References (43)

1. Full activation of chimeric receptors by hybrids between PTH and calcitonin
2. Glucagon-glucagon-like peptide 1 receptor chimeras reveal domains that determine specificity of glucagon binding
3. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells
4. The hydrophobic residues phenylalanine 184 and leucine 187 in the type-1 parathyroid hormone (PTH) receptor functionally interact with the amino-terminal portion of PTH-(1-34)
5. The production of nonpeptidyl growth hormone secretagogue
6. Contribution of the second transmembrane helix of the secretin receptor to the positioning of secretin
7. Role of charged amino acids conserved in the vasoactive intestinal polypeptide/ secretin family of receptors on the secretin receptor functionality
8. Cloning and functional expression of the human glucagon-like peptide (GLP-I) receptor
9. Demonstration of a direct interaction between residue 22 in the carboxyl-terminal half of secretin and the amino-terminal tail of the secretin receptor using photoaffinity labeling
10. Identification of an interaction between residue 6 of the natural peptide ligand and a distinct residue within the amino-terminal tail of the secretin receptor
11. Glucagon-like peptides
12. Aspartate 196 in the first extracellular loop of the human VIP1 receptor is essential for VIP binding and VIP-stimulated cAMP production
13. Cell and molecular biology of the incretin hormones glucagon-like peptide 1 and glucose-dependent insulin releasing polypeptide
14. Localization of the domains involved in ligand binding and activation of the glucose-dependent insulinotropic polypeptide receptor
15. The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors
16. Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: Neuroprotective drug design
17. The amino terminal domain of the glucagon-like peptide-1 receptor is a critical determinant of subtype specificity
18. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus
19. Glucagon-like peptide-1 enhances the insulinotropic effect of glibenclamide in NIDDM patients and the perfused rat pancreas
20. Ligand binding to the aminoterminal domain of the mGluR4 subtype of metabotropic glutamate receptor
21. Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation
22. Glucagon and GLP-1 receptors: Lessons from chimeric ligands and receptors
23. Critical contributions of amino-terminal extracellular domains in agonist binding and activation of secretin and VIP receptors
24. Multiple extracellular loop domains contribute critical determinants for agonist binding and activation of the secretin receptor
25. G protein-coupled receptors. I. Diversity of receptor-ligand interactions
26. G-protein-coupled receptor heterodimerization modulates receptor function
27. Molecular basis of the little mouse phenotype and implications for cell type-specific growth
28. Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells
29. Insulinotropic action of glucagonlike peptide-1-(7-37) in diabetic and nondiabetic subjects
30. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
31. Dopamine D2 receptor dimers and receptor-blocking peptides
32. Mutations to the third cytoplasmic domain of the glucagon-like peptide 1 (GLP-1) receptor can functionally uncouple GLP-1-stimulated insulin secretion in HIT-T15 cells
33. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs
34. Expression cloning of the pancreatic β cell receptor for the gluco-incretin hormone glucagon-like peptide 1
35. Glucagon-like peptide-1 and the control of insulin secretion in normal and in NIDDM
36. Exchange of W39 by A within the N-terminal extracellular domain of the GLP-1 receptors results in a loss of receptor function
37. Glucagon-like peptide-1 regulates the beta cell transcription factor, PDX-1, in insulinoma cells
38. Characterization of the carboxyl-terminal domain of the rat glucose-dependent insulinotropic polypeptide (GIP) receptor. A role for serines 426 and 427 in regulating the rate of internalization
39. The isolated N-terminal extracellular domain of the glucagon-like peptide-1 (GLP)-1 receptor has intrinsic binding activity
40. The isolated N-terminal extracellular domain of the glucagon-like peptide-1 (GLP)-1 receptor has intrinsic binding activity
41. Five out of six tryptophan residues in the N-terminal extracellular domain of the rat GLP-1 receptor are essential for its ability to bind GLP-1
42. Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats